Arcus Biosciences (RCUS) Form 144: sell 100,000 shares, $1.99M

Arcus Biosciences (RCUS): Notice of proposed sale under Form 144.

Accepted by SEC EDGAR 10/28/2025 - 05:09 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Arcus Biosciences (RCUS): Notice of proposed sale under Form 144. A security holder filed to sell 100,000 shares of Class A common stock through Goldman Sachs & Co. LLC on the NYSE, with an aggregate market value of $1,988,000. The approximate sale date is 10/28/2025.

The shares were originally acquired from the issuer in a private transaction on 05/29/2015, with payment on the same date. Shares outstanding were 106,430,976, providing scale context for the proposed sale.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Arcus Biosciences (RCUS) disclose in this Form 144?

A holder plans to sell 100,000 shares of Class A common stock with an aggregate market value of $1,988,000.

When is the planned sale date for the RCUS shares?

The filing lists an approximate sale date of 10/28/2025.

Which broker will handle the proposed RCUS share sale?

The broker is Goldman Sachs & Co. LLC, 200 West Street, New York, NY 10282.

On which exchange are the RCUS shares listed for this sale?

The filing names the NYSE.

How many RCUS shares are outstanding for context?

The filing shows 106,430,976 shares outstanding.

When and how were the shares to be sold originally acquired?

They were acquired from the issuer in a private transaction on 05/29/2015, with payment on the same date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001422996
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Arcus Biosciences, Inc.
SEC File Number	001-38419
Address of Issuer	3928 Point Eden Way Hayward CALIFORNIA 94545
Phone	1-510-694-6200
Name of Person for Whose Account the Securities are To Be Sold	Juan Jaen
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Class A Common Stock	Goldman Sachs & Co. LLC 200 West Street New York NY 10282	100000	1988000	106430976	10/28/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Class A Common Stock	05/29/2015	Acquired from issuer in private transaction	The Issuer			100000	05/29/2015	None

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	The sales of shares set forth herein are made in connection with a selling plan dated 8/12/2024, that is intended to comply with Rule 10b5-1(c). All shares to be sold by the Juan Carlos Jaen and Anita Galeana 2000 Trust.
Date of Notice	10/28/2025
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	08/12/2024
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Goldman Sachs & Co. LLC on behalf of Juan Jaen
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)